9月21日，英国剑桥大学Christ's 学院（University of Cambridge）Christopher Abell教授应邀在药物所进行了学术交流。

Abell教授在基于碎片的药物发现中有着非常成功的经验，此次来访在药物所做了题为“Fragment based approaches in drug discovery and chemical biology”的学术报告并受到了与会科研人员的热烈欢迎。Abell教授介绍了基于小分子碎片化合物库与结构生物学的药物设计方法，在现代药物开发技术领域，基于片段的药物筛选是新兴的高通量筛选的替代办法。会后Abell教授与药物所相关领域的课题组进行深入交流并达成合作意向。

Abell教授研究方向主要是基于碎片的药物发现与化学生物学研究，发展了microdroplet相关技术。先后在Nature，Angew. Chem.等著名杂志发表200多学术论文，并创立多家公司，包括在美国纳斯达克上市的Astex制药公司。

（新闻来源：沈竞康课题组）

Professor Christopher Abell from University of Cambridge Visits Shanghai Institute of Materia Medica

On 21 September 2011, Professor Christopher Abell from the University of Cambridge visited Shanghai Institute of Materia Medica and delivered an academic lecture titled ‘Fragment based approaches in drug discovery and chemical biology’, which focused on the progress and challenges in fragment-based drug discovery, and its applications in the field of chemical biology. Fragment-Based Drug Discovery has been considered as an alternative approach for drug discovery of enzyme targets.

 

Professor Abell’s research interests focus mainly on the fragment-based approaches for drug discovery and chemical biology as well as the development of microdroplet technology in chemistry and biology. He has numerous research publications, including papers in Nature, Angew. Chem. Int. Ed.. He is one of the co-founders of several well-known biotechnical companies, including Astex Therapeutics (NASDAQ:ASTX).

 

(Source of News: Prof. Shen Jingkang’s research group)